- Home
- CSTL vs XFLT Comparison
CSTL vs XFLT Comparison
Compare CSTL & XFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- XFLT
- Stock Information
- Founded
- CSTL 2007
- XFLT 2017
- Country
- CSTL United States
- XFLT United States
- Employees
- CSTL N/A
- XFLT N/A
- Industry
- CSTL Medical Specialities
- XFLT Investment Managers
- Sector
- CSTL Health Care
- XFLT Finance
- Exchange
- CSTL Nasdaq
- XFLT Nasdaq
- Market Cap
- CSTL 456.2M
- XFLT 439.2M
- IPO Year
- CSTL 2019
- XFLT N/A
- Fundamental
- Price
- CSTL $19.46
- XFLT $5.68
- Analyst Decision
- CSTL Strong Buy
- XFLT
- Analyst Count
- CSTL 6
- XFLT 0
- Target Price
- CSTL $37.67
- XFLT N/A
- AVG Volume (30 Days)
- CSTL 462.3K
- XFLT 336.2K
- Earning Date
- CSTL 08-04-2025
- XFLT 01-01-0001
- Dividend Yield
- CSTL N/A
- XFLT 14.17%
- EPS Growth
- CSTL N/A
- XFLT N/A
- EPS
- CSTL N/A
- XFLT N/A
- Revenue
- CSTL $347,083,000.00
- XFLT N/A
- Revenue This Year
- CSTL N/A
- XFLT N/A
- Revenue Next Year
- CSTL $1.36
- XFLT N/A
- P/E Ratio
- CSTL N/A
- XFLT N/A
- Revenue Growth
- CSTL 38.43
- XFLT N/A
- 52 Week Low
- CSTL $15.45
- XFLT $6.01
- 52 Week High
- CSTL $35.84
- XFLT $7.76
- Technical
- Relative Strength Index (RSI)
- CSTL 55.41
- XFLT 53.32
- Support Level
- CSTL $18.18
- XFLT $5.45
- Resistance Level
- CSTL $20.63
- XFLT $5.59
- Average True Range (ATR)
- CSTL 0.77
- XFLT 0.06
- MACD
- CSTL 0.07
- XFLT 0.01
- Stochastic Oscillator
- CSTL 57.36
- XFLT 85.19
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About XFLT XAI Octagon Floating Rate & Alternative Income Term Trust of Beneficial Interest
XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.